Formation of Glyco-Functionalized Platinum Complexes by Cross-Metathesis and Evaluation of Their Efficacy in Inhibition of Lung Tumor Cell Lines

Möker, Janina; Salge-Bartels, Ursula; Thiem, Joachim

doi:10.1080/07328303.2012.739231

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97,98 A larger set of complexes with a ranges of different sugars similarly incorporated into a malonate leaving group ligand were prepared, but the results of the biological assays with these complexes have yet to be released. 99 For the sake of brevity, the remainder of the discussion of sugar conjugates will focus on those complexes for which experiments have been done to characterize the mechanism of uptake.…”

Section: Platinum(ii) Compounds With a Mechanism Of Action Similarmentioning

confidence: 99%

“…96 Glucose can alternatively be incorporated into a leaving group ligand such as malonate, but an early study reported no increase in activity for such a construct over the analogous carboplatin. 97,98 A larger set of complexes with a range of different sugars was prepared, but the results of biological assays with these complexes have yet to be released. 99 Readers interested in a comprehensive overview of platinum−glucose conjugates are referred to a recent review.…”

Section: The Next Generation Of Cisplatin-like Platinum(ii) Complexesmentioning

confidence: 99%

See 1 more Smart Citation

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.

show abstract

Section: Platinum(ii) Compounds With a Mechanism Of Action Similarmentioning

confidence: 99%

Section: The Next Generation Of Cisplatin-like Platinum(ii) Complexesmentioning

confidence: 99%

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

show abstract

“…in 2009: these are characterized by the presence of a butyl spacer, which connects a malonic moiety to the carbohydrate (Figure 28). Similar compounds were developed few years later, in order to achieve an improved cytotoxicity value especially towards non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [87,88] …”

Section: Metal Complexes As Cancer Therapeutic Agentsmentioning

confidence: 99%

Glycoconjugated Metal Complexes as Cancer Diagnostic and Therapeutic Agents

et al. 2020

View full text Add to dashboard Cite

The possibility of selectively delivering metal complexes to a defined cohort of cells on the basis of their metabolic features is a highly challenging goal, which may be extremely useful for a series of purposes, including diagnosis and therapy of pathological states, such as cancer. Tumor cells display augmented requests for carbohydrates and, in particular, for glucose in order to sustain their high proliferation rate, which causes an increased glycolytic process (Warburg effect). Since several metal complexes display diagnostic and/or therapeutic properties, their conjugation to carbohydrate portions often induce their preferential accumulation in cancer cells, similarly to what is observed with fluorodeoxyglucose (FDG). In this review we have considered the latest developments of glycoconjugates containing metal complexes in their structures. These compounds are classified as diagnostic or therapeutic agents and are further systematically discussed on the basis of the metal atom they contain. Several diagnostic techniques are possible with these probes, since, depending on the metal species included in their structures, they may be employed in nuclear medicine (PET, SPECT), magnetic resonance imaging, luminescence and phosphorescence. At the same time, the lack of selective cytotoxicity displayed by several metal‐based chemotherapeutic agents, may also be solved by the conjugation of these agents to carbohydrate portions. Overall, data so far available reveal the great potential of this chemical class in the early detection and in the cure of severe neoplastic diseases, which still needs to be fully explored in the clinic.

show abstract

“…Moker et al reported on a number of similar carboplatin glycoconjugates in which the malonato ligand was linked to a glucose molecule at the unusual C(3) position through an alkyl spacer (Pt-16), but no significant improvements in terms of cytotoxic activity were recorded (compared with carboplatin) [77][78][79].…”

Section: Glyco-appended Derivativesmentioning

confidence: 99%

Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy

Pettenuzzo¹,

Pigot²,

Ronconi³

2016

Metallodrugs

View full text Add to dashboard Cite

Glucose is a key source of energy and an essential nutrient for cell growth. Rapidly dividing cancer cells are well-known to require more nutrients and energy than normal ones to sustain their higher proliferation rates, and glucose is no exception. Therefore, the biomolecules involved in the promotion/regulation of the glycolytic flux may be regarded as potential targets for tackling tumor progression. Among all, glucose transporters (GLUTs), devoted to the recognition and cellular internalization of glucose, are largely overexpressed in tumors, thus indicating glycolysis as the major anaerobic glucose metabolism. Accordingly, such increased demand of glucose by fast-proliferating cancer cells makes it very attractive to selectively target tumor sites. In particular, tailored glucose-like substrates can be conjugated to chemotherapeutics (including metal-containing anticancer agents) so as to attain the site-specific delivery of drugs into the affected tissues. Progress in the development of metal-based glycoconjugates are here summarized and discussed.

show abstract

Formation of Glyco-Functionalized Platinum Complexes by Cross-Metathesis and Evaluation of Their Efficacy in Inhibition of Lung Tumor Cell Lines

Cited by 9 publications

References 17 publications

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

Glycoconjugated Metal Complexes as Cancer Diagnostic and Therapeutic Agents

Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy

Contact Info

Product

Resources

About